Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH | P47989 | 5/20 | 0.38 |
| ▸ | CDK1 | P06493 | 1/20 | 0.35 |
| ▸ | CDK4 | P11802 | 1/20 | 0.35 |
| ▸ | CDK2 | P24941 | 1/20 | 0.35 |
| ▸ | PNP | P00491 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | BLM | P54132 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | PSMB8 | P28062 | 2/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | MITF | O75030 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | HBB | P68871 | 1/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
| ▸ | TYMS | P04818 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19253573 | 0.84 | PSMB8 (0.35) | PSMB8GAA | |
| SCHEMBL731953 | 0.81 | — | — | |
| SCHEMBL2417370 | 0.71 | PNP (0.66) | PNPMAPTTHRB | |
| SCHEMBL796035 | 0.70 | L3MBTL1 (0.44) | XDHPSMB8 | |
| SCHEMBL14264257 | 0.65 | — | — | |
| SCHEMBL796034 | 0.65 | XDH (0.38) | XDHCDK1CDK4CDK2PNP | |
| SCHEMBL1020020 | 0.64 | PSMB8 (0.32) | PSMB8 | |
| SCHEMBL9781236 | 0.64 | LMNA (0.40) | PSMB8 | |
| SCHEMBL10841966 | 0.62 | USP8 (0.40) | PSMB8 | |
| SCHEMBL31589910 | 0.61 | PDPK1 (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2616465-B1 | TRIAZINE-OXADIAZOLES | NOVARTIS AG (CH) | 2015-11-04 | — | — | EP | disclosed |
| US-20150025057-A1 | Triazine-oxadiazoles | NOVARTIS AG (CH) | 2015-01-22 | — | — | US | disclosed |
| US-20150025057-A1 | Triazine-oxadiazoles | NOVARTIS AG (CH) | 2015-01-22 | — | — | US | disclosed |
| US-8895733-B2 | Triazine-oxadiazoles | NOVARTIS AG (CH) | 2014-11-25 | — | — | US | disclosed |
| US-8895733-B2 | Triazine-oxadiazoles | NOVARTIS AG (CH) | 2014-11-25 | — | — | US | disclosed |
| US-20140051676-A1 | Triazine-oxadiazoles | NOVARTIS AG (CH) | 2014-02-20 | — | — | US | disclosed |
| US-20140051676-A1 | Triazine-oxadiazoles | NOVARTIS AG (CH) | 2014-02-20 | — | — | US | disclosed |
| WO-2012035023-A1 | TRIAZINE-OXADIAZOLES | NOVARTIS AG (CH) | 2012-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150025057-A1 | Triazine-oxadiazoles | OPRK1, OPRD1, OPRL1 | XDH 394/4885CDK1 697/4885CDK4 708/4885 |
| US-20140051676-A1 | Triazine-oxadiazoles | OPRK1, OPRD1, OPRL1 | XDH 394/4885CDK1 697/4885CDK4 708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.